. Author manuscript; available in PMC: 2022 Mar 1.

Published in final edited form as: Ann Allergy Asthma Immunol. 2020 Dec 11;126(3):284–291.e2. doi: 10.1016/j.anai.2020.12.005

e-Table 1.

Sensitivity analysis on IGF-1 and asthma

	All participants	Women	Men

IGF-1 quartile (nmol/L)	Odds Ratio (95% Confidence Interval)

Excluding participants with a diagnosis of emphysema or chronic bronchitis	n=293,114	n=158,226	n=134,888
Q1 (< 17.6)	1.0	1.0	1.0
Q2 (17.6– < 21.3)	0.93 (0.90–0.97)^†	0.95 (0.91–0.99)^*	0.92 (0.87–0.96)^†
Q3 (21.3– < 24.9)	0.90 (0.87–0.93)^†	0.91 (0.87–0.95)^†	0.87 (0.83–0.92)^†
Q4 (≥ 24.9)	0.87 (0.84–0.90)^†‡	0.87 (0.85–0.93)^†‡	0.85 (0.81–0.90)^†‡
Multiple imputation	n=439,760	n=242,249	n=197,511
Q1 (< 17.6)	1.0	1.0	1.0
Q2 (17.6– < 21.3)	0.92 (0.90–0.95)^†	0.92 (0.89–0.96)^†	0.92 (0.88–0.96)^†
Q3 (21.3– < 24.9)	0.89 (0.87–0.92)^†	0.91 (0.88–0.94)^†	0.88 (0.84–0.92)^†
Q4 (≥ 24.9)	0.88 (0.85–0.90)^†‡	0.89 (0.86–0.92)^†‡	0.86 (0.83–0.90)^†‡

All models adjusted for age, sex (in all participants), ethnicity, annual household income, body mass index, smoking status, pack-years of cigarette smoking, the season of the examination, the time of the day when the examination was performed, serum level of glycated hemoglobin A1c, and C-reactive protein.

P <0.05

^†

P <0.05

^‡

P for trend <0.05